Obesity Advancements: Regeneron’s Triplet Breakthrough, $2B Hansoh Deal, Biocon’s Diabesity Bet & More
In this week’s Obesity Updates, we spotlight the top global moves reshaping obesity treatment—from powerful new drug combinations and billion-dollar biotech deals to emerging market competition and novel pipelines in Asia.
Key updates include:
💉 Regeneron’s triplet therapy shows fat loss with muscle preservation
💰 Regeneron strikes $2B deal with Hansoh for phase 3 GLP-1/GIP drug
🇮🇳 Biocon expands GLP-1 footprint to target global “diabesity” market
🇨🇳 Novo Nordisk faces 60+ rivals as China patent expiry looms
🇰🇷 Hanmi & Daewoong advance muscle-boosting GLP-1 pipelines
Discover how biotech innovators across the U.S., China, India, and South Korea are racing to redefine the obesity landscape through data, partnerships, and global ambition.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #GLP1Therapies #ObesityTreatment #BiotechNews #Regeneron #Semaglutide #Biocon #NovoNordisk #HanmiPharma #Daewoong #PharmaInnovation #LucidQuest #ClinicalTrials #WeightLossScience